RxDoctor Payments Data

Maaz Iqbal, MD

Interventional Pain Medicine · Mesa, AZNPI 1760778906

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.8% of the total across 270 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Abbott at 56.7% of the total. Reporting peaked in 2024 at $1,908 and has fallen 55.6% since, to $848 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in AZ, where the typical reported total is $8,993.

$10,273in general payments, 2019–2025

Across 270 payments — averaging $38.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$6K
  • Nevro Corp.$1K
  • Boston Scientific$777
  • Medtronic$728
  • Saluda Medical Americas, Inc.$493
  • SPR Therapeutics, Inc$415
  • plus $851 from 15 others
$262,882in research payments, 2019–2025

Across 35 payments — averaging $7510.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$263K

What the payments were for

  • Travel & lodging$9509%
  • Food & beverage$9,32391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,273 in reported general payments places this provider in the 50th percentile of 64 interventional pain medicine providers in Arizona.

See all interventional pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$217,485
Medicare patients
192
Services billed
3,429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen314$8,257
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen319$7,517
Oxycodone Hcl117$1,550
Tramadol Hcl217$1,356
Gabapentin99$1,085
Tizanidine Hcl112$841
Methocarbamol47$836
Pregabalin61$653
Cyclobenzaprine Hcl76$609
Morphine Sulfate ErMorphine Sulfate21$548
Celecoxib13$381
Duloxetine Hcl11$261
Ibuprofen20$226
Meloxicam40$79
Diazepam12$11

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →